News

Filter

Current filters:

BiosimilarsGlobal

Pfenex soars on Lucentis biosimilar deal with Hospira

Pfenex soars on Lucentis biosimilar deal with Hospira

10-02-2015

Shares of US clinical-stage biotech firm Pfenex leapt 28% to $8.85 in morning trading, after the company…

BiosimilarsBiotechnologyGenentechGlobalHospiraLicensingLucentisNovartisOphthalmicsPF582PfenexResearchRoche

Global oncology biosimilars market 2014-2018

28-11-2014

The global oncology biosimilars market is expected to expand at a compound annual growth rate (CAGR)…

BioconBiosimilarsCellTrionDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingMylanSandoz

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

03-11-2014

Although 80% of rheumatologists surveyed by data and research firm Decision Resources Group prescribe…

Anti-Arthritics/RheumaticsBiosimilarsGlobalPfizerPharmaceuticalResearchXeljanz

Biosimilars set to revolutionize global drug development industry, says report

Biosimilars set to revolutionize global drug development industry, says report

30-09-2014

Intellectual Property and Science business of Thomson Reuters today announced the release of Biosimilars:…

BiosimilarsBiotechnologyGlobalMarkets & MarketingResearch

Lucrative biosimilars space to erode biologics market from 2019

Lucrative biosimilars space to erode biologics market from 2019

11-06-2014

The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market…

BiosimilarsBiotechnologyGlobalMarkets & MarketingRegulation

European generics group welcomes WHA resolution on biotherapeutics products

04-06-2014

The European Generic Medicines Association (EGA) has welcomed the 67th World Health Assembly’s Resolution…

BiosimilarsGenericsGlobalRegulation

EGA Biosimilars: European monitoring and global business opportunities

EGA Biosimilars: European monitoring and global business opportunities

07-04-2014

The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s…

BiosimilarsEuropeGlobalInterviewsMarkets & Marketing

Promising late-stage GI drugs could stabilize global market decline; report

16-01-2014

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis…

BiosimilarsGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Back to top